Clinical trial
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections…
NCT00085878 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00085878 |
|---|---|
| Title | Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors |
| Official title | A Phase I, Dose Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Daily Subcutaneous Injections in Adult Patients With Solid Tumors |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor Cancer |
| Intervention type | Drug |
| Interventions | SB-485232 |
| Enrollment | 25 |
| Start date | Jan 1, 2003 |
| First posted | Jun 18, 2004 |
| Last update posted | Oct 16, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: